• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    2/8/24 4:16:56 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHVS alert in real time by email
    SC 13G/A 1 d582194dsc13ga.htm SC 13G/A SC 13G/A

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    Pharvaris, N.V.

    (Name of Issuer)

    Ordinary Shares

    (Title of Class of Securities)

    N69605108

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. N69605108    Schedule 13G    Page 1 of 6

     

     1   

     Names of Reporting Persons

     

     LSP V Coöperatieve U.A.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     The Netherlands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     3,556,805

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     3,556,805

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,556,805

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     6.8%

    12  

     Type of Reporting Person

     

     OO (Limited Liability Company)

     


    CUSIP No. N69605108    Schedule 13G    Page 2 of 6

     

     1   

     Names of Reporting Persons

     

     LSP V Management B.V.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     The Netherlands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     3,556,805

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     3,556,805

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,556,805

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     6.8%

    12  

     Type of Reporting Person

     

     OO (Limited Liability Company)

     

     


    CUSIP No. N69605108    Schedule 13G    Page 3 of 6

     

    ITEM 1.

    (a)   Name of Issuer:

    Pharvaris, N.V. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    J.H. Oortweg 21, 2333 CH Leiden, The Netherlands

     

    ITEM 2.

    (a)   Name of Person Filing:

    This statement is being filed on behalf of LSP V Coöperatieve U.A. (“LSP V”) and LSP V Management B.V. (each a “Reporting Person” and, collectively, the “Reporting Persons”).

     

      (b)

    Address or Principal Business Office:

    The business address of the Reporting Persons is Johannes Vermeerplein 9, 1071 DV Amsterdam, The Netherlands.

     

      (c)

    Citizenship of each Reporting Person is:

    Each of the Reporting Persons is organized under the laws of The Netherlands. 

     

      (d)

    Title of Class of Securities:

    Ordinary Shares, par value € 0.12 per share (“Ordinary Shares”).

     

      (e)

    CUSIP Number:

    N69605108

     

    ITEM 3.

    Not applicable.

     

    ITEM 4.

    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of Ordinary Shares of the Issuer as of December 31, 2023, based upon 52,108,675 Ordinary Shares outstanding as reported by the Issuer in its prospectus supplement filed with the Securities and Exchange Commission pursuant to Rule 424(b)(5) on December 7, 2023.


    CUSIP No. N69605108    Schedule 13G    Page 4 of 6

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

       

    Sole power
    to vote or to
    direct the

    vote:

         Shared power
    to vote or to
    direct the vote:
        

    Sole

    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    LSP V Coöperatieve U.A.

         3,556,805        6.8 %      0        3,556,805        0        3,556,805  

    LSP V Management B.V

         3,556,805        6.8 %      0        3,556,805        0        3,556,805  

    LSP V is the record holder of 3,556,805 Ordinary Shares. LSP V Management B.V. is the sole director of LSP V. The managing directors of LSP V Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP V Management B.V., Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to beneficially own the Ordinary Shares held of record by LSP V. Each of Mr. Kleijwegt, Mr. Kuijten and Mr. Rothe disclaims beneficial ownership of such shares.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    Not applicable.


    CUSIP No. N69605108    Schedule 13G    Page 5 of 6

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 8, 2024

     

    LSP V Coöperatieve U.A.
    By:  

    /s/ Martijn Kleijwegt

    Name: LSP V Management B.V.
    Title: Managing Director
    Name: Martijn Kleijwegt
    Title: Managing Director
    By:  

    /s/ René Kuijten

    Name: LSP V Management B.V.
    Title: Managing Director
    Name: René Kuijten
    Title: Managing Director
    LSP V Management B.V.
    By:  

    /s/ Martijn Kleijwegt

    Name: Martijn Kleijwegt
    Title: Managing Director
    By:  

    /s/ René Kuijten

    Name: René Kuijten
    Title: Managing Director


    CUSIP No. N69605108    Schedule 13G    Page 6 of 6

     

    LIST OF EXHIBITS

     

    Exhibit
    No.

      

    Description

    99    Joint Filing Agreement (previously filed).
    Get the next $PHVS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHVS

    DatePrice TargetRatingAnalyst
    6/11/2025$32.00Buy
    Guggenheim
    4/29/2025$28.00Overweight
    Cantor Fitzgerald
    9/25/2023$27.00Outperform
    Wedbush
    8/15/2023$10.00 → $34.00Equal-Weight → Overweight
    Morgan Stanley
    10/5/2022$16.00Buy
    Bryan Garnier
    9/13/2022$34.00 → $18.00Mkt Outperform
    JMP Securities
    8/23/2022$40.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    8/22/2022$26.00 → $13.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $PHVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

    Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks, on track; study is expected to initiate by YE2025Strong financial position with cash and cash equivalents of €200 million as of June 30, 2025; subsequent closing of $201 million public offering extends cash runway into 1H2027 ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Phar

    8/12/25 4:05:00 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

    ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the closing of its previously announced upsized underwritten public offering of 9,562,500 ordinary shares (which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,312,500 ordinary shares) and pre-funded warrants to purchase 500,000 ordinary shares. The gross proc

    7/24/25 4:05:58 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

    ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shar

    7/22/25 9:22:41 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Pharvaris N.V. with a new price target

    Guggenheim initiated coverage of Pharvaris N.V. with a rating of Buy and set a new price target of $32.00

    6/11/25 7:54:51 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Pharvaris N.V. with a new price target

    Cantor Fitzgerald initiated coverage of Pharvaris N.V. with a rating of Overweight and set a new price target of $28.00

    4/29/25 8:11:22 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Pharvaris N.V. with a new price target

    Wedbush initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $27.00

    9/25/23 7:40:10 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Pharvaris N.V.

    SCHEDULE 13G/A - Pharvaris N.V. (0001830487) (Subject)

    8/14/25 5:56:17 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Pharvaris N.V.

    6-K - Pharvaris N.V. (0001830487) (Filer)

    8/12/25 4:10:22 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Pharvaris N.V.

    6-K - Pharvaris N.V. (0001830487) (Filer)

    7/24/25 4:18:38 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Announces Appointment of Elisabeth Björk as Board Member

    NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl

    6/17/25 7:00:00 AM ET
    $PHVS
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicore Expands and Strengthens its Board of Directors

    STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

    5/14/24 2:20:00 AM ET
    $KRON
    $MACK
    $MXCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Biotechnology: Laboratory Analytical Instruments

    Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

    ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities

    11/15/23 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/14/24 8:42:52 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/14/24 10:27:18 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/13/24 2:14:59 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Financials

    Live finance-specific insights

    View All

    Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

    CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece

    9/5/24 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

    Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo92.3% reduction in occurrence of moderate and severe attacks92.6% fewer attacks treated with on-demand medication by participantsDeucrictibant well-toleratedPharvaris to host a conference call today at 8:00 a.m. EST ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoi

    12/6/23 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

    Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks. Pharvaris plans to present data from the study at future medical meetings. RAPIDe-1 Clinical Stu

    12/8/22 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care